Auriga Maintains a 'Buy' on DepoMed (DEPO); Actavis Filed Paragraph IV Certification; No Generic Expected Any Time Soon

Auriga maintains a 'Buy' on DepoMed Inc (NASDAQ: DEPO) price target of $7.00.

Auriga analyst said, "The announcement (after market close on 1/23) of a paragraph IV filing on Gralise is not likely to weigh on the shares in our view. We view Gralise as a well-protected long term asset through orphan drug exclusivity and a portfolio of large number of patents on the formulation, dosage and use. We do not expect shares to react negatively to the news, but if they do, we would be buyers on the weakness."

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $6.32 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Piper Sandler Downgrades Magnolia Oil & Gas Corp. (MGY) to Neutral
• Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners